Retavase Generic Name & Formulations
Kit—1 (2 vials w. diluents, supplies); Half-Kit—1 (1 vial w. diluent, supplies)
Mechanism of Action
Reteplase is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Treatment of acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure.
Limitations of Use
The risk of stroke may outweigh the benefit produced by thrombolytic
therapy in patients whose STEMI puts them at low risk for death or heart failure.
Retavase Dosage and Administration
Start as soon as possible after onset of STEMI. 10 units IV over 2mins; repeat with 10 units 30mins after the first dose.
Active internal bleeding. Recent stroke. Intracranial or intraspinal surgery or serious head trauma within 3 months. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Retavase Boxed Warnings
Avoid noncompressible arterial puncture, internal jugular and subclavian venous punctures, IM inj, nonessential handling of patient to minimize risk of bleeding. Withhold second dose if serious bleeding or anaphylactoid reaction occurs. Discontinue concomitant anticoagulant therapy if severe bleeding occurs. Cholesterol embolization. Pregnancy. Nursing mothers: not studied.
Increased bleeding risk with concomitant anticoagulant therapy. Incompatible with heparin; do not administer through an IV line together. Coagulation tests may be unreliable during therapy.
Retavase Adverse Reactions
Bleeding, hypersensitivity reactions, cholesterol embolism.
Retavase Clinical Trials
Retavase Patient Counseling